AvivoClin Adds Microdosing, Central Lab Services

Azopharma Product Development Group has added microdosing and central lab services to its clinical pharmacology research facility, AvivoClin Clinical Services, in Daytona Beach, FL. The additional services will be accommodated by a recent facility expansion that began in March 2008.

Microdosing provides early pharmacokinetic and pharmcodynamic data in humans for pharmaceutical and regulatory agencies. AvivoClin now offers Phase 0 microdosing services that include synthesis and labeling of material, formulation, administration of microdoses, and analysis of samples.

AvivoClin will also offer central lab services in an effort to provide quicker turn-around time for results, a decrease in errors, and a reduction in costs. According to Phil Meeks, chief executive officer of Azopharma, “The increased space and capabilities allow us to better serve the growing needs of our clients. Through AvivoClin, Azopharma Product Development Group can support numerous clinical studies simultaneously resulting in higher level of service.”